RE: Quotient and Open Orphan impact on Genedrive11 May 2020 21:30
This was 1st may so after friday we are into week 3... with more news due anytime..im staying right here.
Manufacturing milestones achieved for SARS-CoV-2 test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces it has completed the last significant manufacturing milestone in the co-development of the Genedrive® 96 SARS-CoV-2 kit with Cytiva. The PCR-based test has completed its pilot manufacturing runs and yielded high performing multiplexed assays for COVID-19 testing. The overall project plan currently remains on track and the company is targeting CE marking in approximately 3 weeks’ time.